Abnormal levels of serum antielastin antibodies in children with diabetes mellitus type 1

Journal of Investigative Medicine

Volumn 54, Issue 8, 2006, Pages 461-467

  Nicoloff, George ^a   Weiss, Antony S ^b   Iotova, Violeta ^c   Tzaneva, Valentina ^c   Petrova, Chayka ^a   Domuschieva, Nadja ^d   Nikolov, Asparuh ^a   Tzvetanov, Plamen ^a   Christova, Petkana ^a  

^a MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

^d NONE

Author keywords

Antielastin antibodies; Diabetes mellitus; Microalbuminuria; Retinopathy

Indexed keywords

ALBUMIN; AUTOANTIBODY; ELASTIN; ELASTIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROALBUMINURIA; PROTEIN DEGRADATION;

EID: 33846414682     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2006.06009     Document Type: Article

References (41)

1. Zhang M, He L, Giro M, et al. Cutis laxa arising from frameshift mutations in exon of the elastin gene (ELN). J Biol Chem 1999;274:981-6.
2. Henin-Pizieux O, Davril M, Han K. Isolation and characterization of desmosine(s) containing peptide tractions of normal and diseases human aortic elastin. Paroi Arterielle 1979;5:41-53.
3. Cambell N. Biology. Redwood City (CA): Benjamin/Cummings; 1990.
4. Baydanoff S, Nicoloff G, Alexiev Ch. Age-dependent changes in the level of antielastin antibodies of different immunoglobulin classes (IgG, IgM, IgA and IgD) in human serum. Cor Vasa 1991;33:197-205.
5. Fulop T, Wei S, Robert L, Jacob MP. Determination of elastin peptides in normal and atherosclerotic human sera by ELISA. Clin Physiol Biochem 1990;8:273-8.
6. Gminski J, Drozdz M, Ulfig-Maslanka R, Najda J. Evaluation of elastin metabolism in children from families with high risk of atherosclerosis. Atherosclerosis 1991;91:185-9.
7. Daskalova M, Taskov H, Dimitrova E, Baydanoff S. Humoral and cellular immune response to elastin in patients with systemic sclerosis. Autoimmunity 1997;25:233-41.
8. Colburn K, Langga-Shariffi E, Kelly G, et al. Abnormalities of serum antielastin antibodies in connective tissue diseases. J Invest Med 2003;51:104-9.
9. Nicoloff G, Blazhev A, Petrova Ch, et al. Detection of free anti-elastin antibodies among diabetic children. J Invest Med 2005;53:128-34.
10. Wrenn D, Mecham R. Immunology of elastin. Methods Enzymol 1987;144:246-59.
11. Vrhovski B, Weiss AS. Biochemistry of tropoelastin. Eur J Biochem 1998;258:1-18.
12. Looker T, Berry C. Growth and development of the rat aorta. II. Changes in nucleic acid and scleroprotein content. J Anat 1972;113:17-34.
13. Baydanoff S, Nicoloff G, Alexiev Ch. Age-related changes in anti-elastin antibodies in serum from normal and atherosclerotic human subjects. Atherosclerosis 1987;63:267-71.
14. Baydanoff S, Nicoloff G, Alexiev Ch. Age-related changes in the level of circulating elastin-derived peptides in serum from normal and atherosclerotic subjects. Atherosclerosis 1987;66:163-8.
15. Colburn K, Kelly G, Malto M, et al. Serum anti-tropo: anti-alpha elastin antibody ratio assessing elastin turnover in scleroderma. Clin Rheumatol 1992;11:206-10.
16. Childhood diabetes - ISPAD Guidelines. Ed. PGF Swift. Publ. Medforum, Zeist, Netherlands. 2000.
17. Nicoloff G, Baydanoff S, Stanimirova N, et al. An association of anti-elastin IgA antibodies with development of retinopathy in diabetic children. Gen Pharmacol 2000;35:83-7.
18. Martin S, Vrhovski B, Weiss A. Total synthesis and expression in Escherichia coli of a gene encoding human tropoelastin. Gene 1995;154:159-66.
19. Wu W, Vrhovski B, Weiss AS. Glycosaminoglycans mediate the coacervation of human tropoelastin through dominant charge interactions involving lysine side chains. J Biol Chem 1999;274:21719-24.
20. Fourlanos S, Narendran P, Byrnes G, et al. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;46:1661-7.
21. Verge C, Stenger D, Bonifacio E, et al. Combined use of autoantibodies IA-2 autoantibody, GAD autoantibodies, insulin autoantibodies, cytoplasmic islet cell autoantibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 1998;47:1857-66.
22. Hillman M, Torn C, Thorgeirsson H, Landin-Olsson M. IgG4-subclasses of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 2004;47:1984-9.
23. Spiro R. Search for a biochemical basis of diabetic microangiopathy. Diabetologia 1976;12:1-14.
24. Sternberg M, Cohen-Forterre L, Peyroux J. Connective tissue in diabetes mellitus. Biochemical alterations of the intercellular matrix with special reference to proteoglycans, collagens and basement membranes. Diabetes Metab 1985;11:27-50.
25. Hamlin C, Kohn R, Luschin J. Apparent accelerated aging of human collagen in diabetes mellitus. Diabetes 1975;24:902-4.
26. Brownlee M. Glycation products and pathogenesis of diabetic complications. Diabetes Care 1992;15:1835-43.
27. Bucala R, Cerami A, Vlassara H. Advanced glycosylation end products in diabetic complications. Diabetes Rev 1995;3:258-68.
28. Chappey O, Dosquet C, Wautier M, Wautier J. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997;27:97-108.
29. Bako G, Jacob MP, Fulop T, et al. Immunology of elastin: study of anti-elastin peptide antibodies by DOT immunobinding assay. Immunol Lett 1987;15:187-92.
30. Baydanoff S, Nicoloff G, Russev T, Alexiev Ch. Detection of elastin-antielastin circulating immune complexes (CIC) in diabetic patients with vascular damage. Cor Vasa 1988;30:361-7.
31. Maser A, Steenkiste J, Dorman V, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989;38:1456-61.
32. DCCT Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes 1988;37:476-81.
33. O'Brien I, Mcfadden J, Corrall R. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991;79:495-502.
34. Greene D, Sima A, Albers J, Pfeifer M. Diabetic neuropathy. In: Rifkin H, Porte D Jr, editors. Ellenberg and Rifkin's diabetes mellitus. Theory and practice. New York: Elsevier; 1990. p. 710-55.
35. Dyck P, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985;82:2513-7.
36. Malik R, Tesfaye S, Thompson S, et al. Endoneurial localization of microvascular damage in human diabetic neuropathy. Diabetologia 1993;36:454-9.
37. Vinik A, Holland M, Le Beau J, et al. Diabetic neuropathies. Diabetes Care 1992;15:1926-75.
38. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990;81:402-6.
39. Fierro B, Modica A, Cardella F, et al. Nerve conduction velocity and circulating immunocomplexes in type 1 diabetic children. Acta Neurol Scand 1991;83:176-8.
40. Zanone M, Peakman M, Purewal T, et al. Autoantibodies to nervous tissue structures are associated with autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993;36:564-9.
41. Stanilova S, Slavov E. Comparative study of circulating immune complexes quantity detection by three assays-CIF-ELISA, C1q-ELISA and anti-C3 ELISA. J Immunol Methods 2001;253:13-21.